title: Perspectives on the management of hyponatraemia secondary to SIADH across Europe.
abstract: The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is the most common cause of euvolaemic hyponatraemia. However, although first described over 50 years ago, the management of hyponatraemia secondary to SIADH is not always straightforward. Some of the issues surrounding the management of hyponatraemia secondary to SIADH were explored in the European Hyponatraemia Survey completed by attendees of the European Hyponatraemia Network Academy Meeting 2011. This article describes the findings of this survey and the specific issues raised regarding the management of hyponatraemia secondary to SIADH in Europe. Some of these issues - including awareness, education, diagnosis, management and cost considerations of the condition - were common to countries across Europe.
authors.affiliation: Internal Medicine - Nephrology, Erasmus Medical Center, Room H-436, PO Box 2040, 3000 CA Rotterdam, The Netherlands. ejhoorn@gmail.com
authors.forename: Ewout J
authors.initials: EJ
authors.lastname: Hoorn
authors.forename: Pierre-Marc
authors.initials: PM
authors.lastname: Bouloux
authors.forename: Volker
authors.initials: V
authors.lastname: Burst
mesh_terms: D065092:Antidiuretic Hormone Receptor Antagonists; D001364:Awareness; D001552:Benzazepines / Q000191:economics / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D004501:Education, Medical; D005060:Europe; D006801:Humans; D007010:Hyponatremia / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy*; D007177:Inappropriate ADH Syndrome / Q000150:complications*; D009994:Osmolar Concentration; D011379:Prognosis; D011795:Surveys and Questionnaires; D000077602:Tolvaptan; D014556:Urine
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; D000077602:Tolvaptan